Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. [electronic resource]
Producer: 20171204Description: 1002-1017 p. digitalISSN:- 1473-5741
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacokinetics
- Apoptosis -- drug effects
- Cell Cycle -- drug effects
- Cell Growth Processes -- drug effects
- Cell Line, Tumor
- Drug Synergism
- HCT116 Cells
- Histone Deacetylase Inhibitors -- administration & dosage
- Human Umbilical Vein Endothelial Cells
- Humans
- Hydroxamic Acids -- administration & dosage
- MCF-7 Cells
- Male
- Mice
- Mice, SCID
- Neoplasms -- blood supply
- Neovascularization, Pathologic -- drug therapy
- Pentoxifylline -- administration & dosage
- Phosphodiesterase Inhibitors -- administration & dosage
- Random Allocation
- Vorinostat
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.